553
Views
16
CrossRef citations to date
0
Altmetric
Drug Evaluation

AVP-786 as a promising treatment option for Alzheimer’s Disease including agitation

ORCID Icon, , , , &
Pages 783-795 | Received 07 Sep 2020, Accepted 26 Jan 2021, Published online: 26 Feb 2021

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Tomoyuki Nagata, Shunichiro Shinagawa, Shinichiro Nakajima, Yoshihiro Noda & Masaru Mimura. (2022) Pharmacotherapeutic combinations for the treatment of Alzheimer’s disease. Expert Opinion on Pharmacotherapy 23:6, pages 727-737.
Read now

Articles from other publishers (15)

Wenying Liu, Yan Li, Tan Zhao, Min Gong, Xuechu Wang, Yue Zhang, Lingzhi Xu, Wenwen Li, Yan Li & Jianping Jia. (2023) The role of N-methyl-D-aspartate glutamate receptors in Alzheimer’s disease: From pathophysiology to therapeutic approaches. Progress in Neurobiology 231, pages 102534.
Crossref
Xiao-Liang Xu, Wen Zhang & Guo-Wu Rao. (2023) Clinical Application and Synthesis Methods of Deuterated Drugs. Current Medicinal Chemistry 30:36, pages 4096-4129.
Crossref
D.P. Devaanand. (2023) Management of neuropsychiatric symptoms in dementia. Current Opinion in Neurology.
Crossref
Jiaming Cheng, Jie Sheng & Xu Cheng. (2023) Synthesis of Methyl -d 3 Arene via Electrochemical Deuterodefluorination of Trifluoromethyl Arene . Organic Letters 25:30, pages 5602-5607.
Crossref
Rita Maria Concetta Di Martino, Brad D. Maxwell & Tracey Pirali. (2023) Deuterium in drug discovery: progress, opportunities and challenges. Nature Reviews Drug Discovery 22:7, pages 562-584.
Crossref
Christoph U. Correll, Marco Solmi, Samuele Cortese, Maurizio Fava, Mikkel Højlund, Helena C. Kraemer, Roger S. McIntyre, Daniel S. Pine, Lon S. Schneider & John M. Kane. (2023) The future of psychopharmacology: a critical appraisal of ongoing phase 2/3 trials, and of some current trends aiming to de‐risk trial programmes of novel agents. World Psychiatry 22:1, pages 48-74.
Crossref
Puja Chopade, Neha Chopade, Zongmin Zhao, Samir Mitragotri, Rick Liao & Vineeth Chandran Suja. (2022) Alzheimer's and Parkinson's disease therapies in the clinic. Bioengineering & Translational Medicine 8:1.
Crossref
Yuxia Cao, Feng Yu, Yi Lyu & Xianfu Lu. (2022) Promising candidates from drug clinical trials: Implications for clinical treatment of Alzheimer's disease in China. Frontiers in Neurology 13.
Crossref
Andi Liu, Astrid M Manuel, Yulin Dai, Brisa S Fernandes, Nitesh Enduru, Peilin Jia & Zhongming Zhao. (2022) Identifying candidate genes and drug targets for Alzheimer’s disease by an integrative network approach using genetic and brain region-specific proteomic data. Human Molecular Genetics 31:19, pages 3341-3354.
Crossref
Ibtisam Mumtaz, Mir Owais Ayaz, Mohamad Sultan Khan, Umar Manzoor, Mohd Azhardin Ganayee, Aadil Qadir Bhat, Ghulam Hassan Dar, Badrah S. Alghamdi, Anwar M. Hashem, Mohd Jamal Dar, Gulam Md. Ashraf & Tariq Maqbool. (2022) Clinical relevance of biomarkers, new therapeutic approaches, and role of post-translational modifications in the pathogenesis of Alzheimer’s disease. Frontiers in Aging Neuroscience 14.
Crossref
Tomoyuki Nagata, Shunichiro Shinagawa, Keisuke Inamura & Masahiro Shigeta. (2022) Pathogenesis and Personalized Interventions for Pharmacological Treatment-Resistant Neuropsychiatric Symptoms in Alzheimer’s Disease. Journal of Personalized Medicine 12:9, pages 1365.
Crossref
Tanja Veselinović & Irene Neuner. (2022) Progress and Pitfalls in Developing Agents to Treat Neurocognitive Deficits Associated with Schizophrenia. CNS Drugs 36:8, pages 819-858.
Crossref
Xuefeng Gu, Donglin Lai, Shuang Liu, Kaijie Chen, Peng Zhang, Bing Chen, Gang Huang, Xiaoqin Cheng & Changlian Lu. (2022) Hub Genes, Diagnostic Model, and Predicted Drugs Related to Iron Metabolism in Alzheimer's Disease. Frontiers in Aging Neuroscience 14.
Crossref
Jacob P. Sorrentino & Ryan A. Altman. (2022) Fluoroalkylation of Dextromethorphan Improves CNS Exposure and Metabolic Stability. ACS Medicinal Chemistry Letters 13:4, pages 707-713.
Crossref
Rita Khoury. (2022) Deuterated dextromethorphan/quinidine for agitation in Alzheimer’s disease. Neural Regeneration Research 17:5, pages 1013.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.